• The use of tau PET to stage Alzheimer disease according to the braak staging framework 

      Macedo, Arthur C.; Tissot, Cecile; Therriault, Joseph; Servaes, Stijn; Wang, Yi Ting Tina; Fernandez-Arias, Jaime; Rahmouni, Nesrine; Lussier, Firoza Z.; Vermeiren, Marie R.; Bezgin, Gleb Y.; Vitali, Paolo; Ng, Kok Pin; Zimmer, Eduardo Rigon; Guiot, Marie Christine; Pascoal, Tharick Ali; Gauthier, Serge G.; Rosa Neto, Pedro (2023) [Artigo de periódico]
      Amyloid-β plaques and neurofibrillary tangles (NFTs) are the 2 histopathologic hallmarks of Alzheimer disease (AD). On the basis of the pattern of NFT distribution in the brain, Braak and Braak proposed a histopathologic ...
    • A two-step workflow based on plasma p-tau217 to screen for amyloid β positivity with further confirmatory testing only in uncertain cases 

      Brum, Wagner Scheeren; Cullen, Nicholas C.; Janelidze, Shorena; Ashton, Nicholas J.; Zimmer, Eduardo Rigon; Therriault, Joseph; Benedet, Andréa L.; Rahmouni, Nesrine; Tissot, Cecile; Stevenson, Jenna; Servaes, Stijn; Triana-Baltzer, Gallen B.; Kolb, Hartmuth C.; Palmqvist, Sebastian; Stomrud, Erik; Rosa Neto, Pedro; Blennow, Kaj; Hansson, Oskar (2023) [Artigo de periódico]
      Cost-effective strategies for identifying amyloid-β (Aβ) positivity in patients with cognitive impairment are urgently needed with recent approvals of anti-Aβ immunotherapies for Alzheimer’s disease (AD). Blood biomarkers ...